Product identity for D-isoleucine is defined by the (2R,3R)-configuration of 2-amino-3-methylpentanoic acid. The substance is assigned CAS 319-78-8, has a molecular formula of C₆H₁₃NO₂, and has a formula weight of 131.17 g/mol. It is supplied as a white to off-white crystalline powder. Typical commercial designations include D-Isoleucine 98%, D-Isoleucine 99% ee, and Fmoc-D-isoleucine; catalog suffixes and packaging formats are supplier-specific. Standard pack sizes include 25 g, 100 g, 1 kg, and 25 kg HDPE drums with inner polyethylene liners. Because D-isoleucine has the same molecular weight and elemental composition as L-isoleucine, incoming material cannot be identified by CHN analysis alone; the release dossier must include a stereospecific method such as chiral HPLC with an appropriate chiral selector or polarimetric measurement according to USP <781>. Lot-specific data for enantiomeric excess, D-allo-isoleucine content, residual solvent, and residue on ignition are normally reported on the certificate of analysis.

Because D-isoleucine is not a canonical proteinogenic substrate, its use in peptide synthesis requires explicit confirmation of absolute configuration at both C2 and C3. The C3 stereocenter distinguishes it from D-leucine and D-valine; these branched-chain amino acids differ in side-chain length and β-methyl substitution. D-leucine has a 2-methylpropyl side chain and D-valine a 2-propyl side chain, while D-isoleucine has a sec-butyl side chain. This structural distinction affects solubility, coupling efficiency, and chiral recognition. Compared with D-leucine, D-isoleucine introduces an additional methyl group at C3, which increases steric hindrance and reduces coupling rates in peptide synthesis. Compared with D-valine, the sec-butyl side chain of D-isoleucine provides a different crystal packing environment, which can be exploited in diastereomeric salt resolutions. These structural differences are confirmed by FTIR and X-ray powder diffraction rather than by elemental analysis.

Analytical identity for D-isoleucine is established by chiral HPLC or by polarimetry. In a chiral ligand-exchange mode, the stationary phase carries a copper(II) complex, and the mobile phase is an aqueous solution with pH adjusted to the ligand-exchange optimum. Detection at 210 nm is typical because the free amino acid lacks a strong chromophore. Enantiomeric excess is calculated from the area ratio of D-isoleucine to the sum of D-isoleucine and L-isoleucine after correcting for response factors. D-allo-isoleucine and L-allo-isoleucine are quantified separately from area percentages obtained under the same chiral conditions. A method is acceptable only when resolution between D-isoleucine and D-allo-isoleucine meets or exceeds 1.5. For high-purity release, the limit of quantitation for D-allo-isoleucine should be ≤0.05% by area.

What Distinguishes (2R,3R)-D-Isoleucine from L-Isoleucine and D-allo-Isoleucine?

Isoleucine contains two stereogenic centers at C2 and C3. D-isoleucine is the (2R,3R)-enantiomer of L-isoleucine; the two compounds are mirror images and have identical physicochemical properties except for optical rotation and interactions with chiral environments. D-allo-isoleucine is not the enantiomer of L-isoleucine but a diastereomer with (2R,3S)-configuration. This distinction is critical for chromatographic integration and for biological activity. In bacterial protein synthesis, L-isoleucine is charged to tRNA^Ile by isoleucyl-tRNA synthetase; D-isoleucine is not a canonical substrate. In chiral separation, D-isoleucine and D-allo-isoleucine may exhibit different retention on ligand-exchange columns; the method must resolve both C2 and C3 epimers to ensure that D-allo-isoleucine is not reported as the target compound.

DL-isoleucine is typically an equimolar mixture of D- and L-isoleucine rather than a mixture containing allo forms. Reference standards for each stereoisomer are therefore necessary for method qualification. The optical rotation of D-isoleucine is negative in aqueous solution, while L-isoleucine is positive under the same conditions. The absolute value is concentration- and temperature-dependent; a lot-specific certificate should state the measured result and the test method.

The presence of D-allo-isoleucine is a common chiral purity failure in D-isoleucine lots produced by racemization routes. Because D-allo-isoleucine and D-isoleucine are diastereomers, their separation is generally easier than the separation of D- and L-enantiomers, but reversed-phase C18 without a chiral selector cannot resolve them. Method transfer between laboratories therefore requires fixed column temperature, mobile phase pH, and copper(II) concentration.

Typical Release Specifications Are Reported As Dried Basis Values

The following table summarizes common release parameters for a chiral-grade D-isoleucine. Actual acceptance limits are lot-specific and should be taken from the supplier certificate of analysis. Values are expressed on a dried basis where indicated. Test methods are aligned to USP and Ph. Eur. general chapters where applicable.

For solid-phase peptide synthesis, Fmoc-D-isoleucine is produced from the free amino acid using Fmoc-OSu in aqueous dioxane under pH-stat control between 8.5 and 9.0. The resulting protected amino acid is dissolved in DMF for automated peptide synthesizers. Because the β-branched side chain slows activation, coupling with HATU/DIEA requires a double-coupling cycle or extended reaction time. Peptide synthesizer manufacturer protocols for β-branched residues specify prolonged coupling at 50–75 °C under microwave irradiation. Residual water in D-isoleucine above 0.1% can suppress activation efficiency; pre-drying is recommended before use in moisture-sensitive peptide bond formation.

On a production-scale automated peptide synthesizer with modular reactor volumes of 100 mmol to 5 mol, incomplete coupling of D-isoleucine is detected by Kaiser test following the second coupling cycle. Repeating activation at 1.1 equivalents of HATU for 30 min at 75 °C increases coupling efficiency above 99% in optimized sequences. These parameters are equipment-specific and are adjusted by the vendor. If the sequence contains consecutive β-branched residues around D-isoleucine, the protocol may require a capping step with acetic anhydride and pyridine to terminate deletion sequences.

For route scouting, D-isoleucine is also converted to the corresponding α-amino alcohol with borane-THF or sodium borohydride/sulfuric acid. The reduction is exothermic; addition is controlled at 0–5 °C in a jacketed glass reactor. Workup under acidic conditions preserves the C2/C3 configuration. The resulting D-isoleucinol is used as a chiral ligand precursor; residual starting material is monitored by TLC with ninhydrin detection.

In chiral resolution applications, D-isoleucine has been used as a starting material for oxazolidinone auxiliaries. The C2 stereocenter transfers stereochemical information in aldol condensation and enolate alkylation; configuration at C3 influences crystalline intermediate solubility. Published data for this specific configuration is limited, so route-specific validation is required. For method transfer of chiral HPLC, a column oven is required because separation of D-isoleucine and D-allo-isoleucine can shift by several minutes across a 5 °C temperature change. Mobile phase pH must be controlled to ±0.05 units. Poor pH control leads to peak shouldering and incorrect integration. System suitability solutions containing D-isoleucine and D-allo-isoleucine at 0.1% relative concentration are injected before sample sequences.

When D-Isoleucine Replaces L-Isoleucine in Asymmetric Synthesis

When D-isoleucine is substituted for L-isoleucine in a synthetic route, the change affects not only optical rotation but also enzyme recognition and crystal packing. In peptide sequences, replacement with D-isoleucine reduces susceptibility to hydrolysis by serine proteases such as trypsin and chymotrypsin; the half-life extension must be measured under the intended biological matrix. Peptide products containing D-isoleucine therefore require stability-indicating HPLC at 37 °C in phosphate-buffered saline to determine proteolytic resistance.

In pharmacological peptide candidates, substitution with D-isoleucine often requires re-validation of receptor binding and metabolic stability. The altered backbone conformation can change the Ki or EC50 by orders of magnitude; no general prediction is available. Assays such as surface plasmon resonance at 25 °C in HBS-EP buffer are used to compare binding kinetics. Stereochemical identity of the modified peptide is confirmed by acid hydrolysis and chiral amino acid analysis with o-phthalaldehyde plus N-acetyl-L-cysteine derivatization. In mammalian cell culture, L-isoleucine is an essential amino acid; D-isoleucine does not substitute for growth, and media containing D-isoleucine as an impurity may require chiral LC-MS confirmation.

In biocatalytic deracemization, D-isoleucine can be generated from the racemate using D-selective hydrolases or D-amino acid oxidase/peroxidase cascades. The pH and temperature setpoints are enzyme-dependent; the process development report rather than a generic value must govern pilot-scale operation. A typical stirred-tank bioreactor with pH-stat and dissolved-oxygen control is used. Batch-to-batch variability in substrate conversion is reduced by controlling agitation at 300–500 min⁻¹ and sparging at 0.5–1.0 vvm; these ranges are process-specific and must be validated. Published data for this specific configuration is limited, so pilot confirmation is required before scale-up.

Storage, Handling, and Crystallization Windows at Pilot Scale

Long-term storage at 2–8 °C in tightly closed containers under nitrogen is specified for chiral-grade D-isoleucine. Short-term ambient shipment is permitted when the container remains sealed and relative humidity is below 60%; moisture uptake above 0.5% triggers re-drying before use in peptide coupling. The material is incompatible with strong oxidizers and with nitrosating agents; reaction with nitrous acid generates nitrogen and hydroxyl acid derivatives. Avoid contact with strong bases in the presence of water at elevated temperature because racemization at C2 may occur under forcing conditions.

At pilot scale, isolation from aqueous ethanol or methanol/water mixtures requires controlled cooling and seeding. Oiling-out at elevated temperature entrains D-allo-isoleucine and reduces enantiomeric excess. A baffled glass-lined crystallizer with controlled jacket cooling is preferred; seed crystals are added at the cloud point to suppress supersaturation. Published data for this specific crystallization configuration are limited, so each lot must be monitored by chiral HPLC before drying. Vacuum drying in a stainless-steel pan dryer at 40–50 °C and <10 mbar is typical; higher temperature may cause browning and partial decomposition. Spray drying of D-isoleucine solutions is not preferred for high-purity material because rapid evaporation can entrap solvent in amorphous particles and reduce crystallinity. If spray drying is used for formulation intermediates, the inlet temperature should be limited to ≤120 °C and outlet temperature ≤60 °C; these values are not validated for D-isoleucine and must be confirmed.

For pharmaceutical intermediate use, D-isoleucine should be supplied with a minimum GMP documentation package including residual solvent data per ICH Q3C, elemental impurities per ICH Q3D, and stability data where the material is held beyond retest date. The product is not approved as an active pharmaceutical ingredient; suitability for a specific synthetic step is the responsibility of the user. In the European Economic Area, import or manufacture of D-isoleucine in quantities above 1 tonne per year may require REACH registration. The Safety Data Sheet must be reviewed for classification under EU CLP; the substance is not classified for most hazard classes, but dust explosion risk and local ventilation requirements apply. RoHS obligations are generally not applicable to unbonded amino acid powders supplied for chemical synthesis.